Portfolio North Talks About Noctura 400
PolyPhotonix’s sight-saving sleep mask could save the NHS multi-millions
PolyPhotonix’s Noctura 400 sleep mask is set to benefit NHS patients suffering from diabetic retinopathy, which is a leading cause of blindness in Europe. The mask has been shown to improve and stabilise diabetic eye disease in 96% of patients, making it a non-invasive alternative to current invasive treatments such as eye injections. Improving patient outcomes with an earlier stage intervention could save the NHS £3,000 per patient, with potential cost savings estimated to be over £180m per year if adopted across the NHS. The mask delivers low-level light at a particular wavelength during a patient’s normal hours of sleep, preventing the eyes’ increased demand of oxygen at night and reducing the damaging effects of diabetic retinopathy on patients’ eyesight. Treating diabetic retinopathy patients with the Noctura 400 sleep mask is a cost-effective alternative to existing treatments and prevents problems before they arise, according to Richard Kirk, Chief Executive of PolyPhotonix.
Michelangelo Biasiucci, 64, from London, is one patient whose life has been transformed by using the sleep mask. He said:
“After being referred to the hospital by my GP, I was diagnosed with diabetic retinopathy. Part of my treatment for this was to have injections in my eyes, and looking back, I don’t know how I tolerated them!”
“I was relieved that not so long after, my consultant prescribed the mask. I would say that the mask has given me my life back – not only can I see so much clearer, but it has enabled me to carry out my job safely again. As a driver, I can now work safely again, especially at night, thanks to the mask.”